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Background and Purpose—Lombardia GENS is a multicentre prospective study aimed at diagnosing 5 single-gene disorders 
associated with stroke (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, Fabry 
disease, MELAS [mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes], hereditary cerebral amyloid 
angiopathy, and Marfan syndrome) by applying diagnostic algorithms specific for each clinically suspected disease
Methods—We enrolled a consecutive series of patients with ischemic or hemorrhagic stroke or transient ischemic attack admitted 
in stroke units in the Lombardia region participating in the project. Patients were defined as probable when presenting 
with stroke or transient ischemic attack of unknown etiopathogenic causes, or in the presence of <3 conventional vascular 
risk factors or young age at onset, or positive familial history or of specific clinical features. Patients fulfilling diagnostic 
algorithms specific for each monogenic disease (suspected) were referred for genetic analysis.
Results—In 209 patients (57.4±14.7 years), the application of the disease-specific algorithm identified 227 patients with 
possible monogenic disease. Genetic testing identified pathogenic mutations in 7% of these cases. Familial history of 
stroke was the only significant specific feature that distinguished mutated patients from nonmutated ones. The presence 
of cerebrovascular risk factors did not exclude a genetic disease.
Conclusions—In patients prescreened using a clinical algorithm for monogenic disorders, we identified monogenic causes of 
events in 7% of patients in comparison to the 1% to 5% prevalence reported in previous series.   (Stroke. 2016;47:00-00. 
DOI: 10.1161/STROKEAHA.115.012281.)
Key Words: CADASIL ◼ cerebral amyloid angiopathy, familial ◼ Fabry disease ◼ genetics  
◼ Marfan syndrome ◼ MELAS syndrome ◼ stroke
Although monogenic diseases are considered rare causes of stroke (≈1%–5% of all strokes),1,2 they are probably 
under diagnosed because physicians may not consider them 
in the differential diagnosis and because the wide phenotypic 
spectrum makes differentiation from sporadic cases difficult. 
Deciding which patients to screen for these diseases presents 
a considerable clinical challenge. First, there are limited data 
on the yield of screening for these conditions in stroke popu-
lations. Second, there is little guidance on which phenotypic 
characteristics increase the chance that such screening will be 
positive. This is particularly important because a family his-
tory may be absent for later onset familial conditions, such 
as stroke. Despite this, the identification of a genetic cause of 
stroke is important both for the individual patient and to allow 
presymptomatic testing of other family members, including 
the possibility of prenatal testing.
The Lombardia GENS project3 was established to (1) deter-
mine the frequency of a number of the most common single-
gene disorders causing stroke in a well-characterized stroke 
population in whom there was a clinical suspicion of an under-
lying genetic cause and (2) develop clinical algorithms that 
might assist the clinician in deciding in which patients testing 
for these conditions has a useful yield. Testing was performed 
for 5 single-gene disorders associated with stroke: cerebral auto-
somal dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL; #MIM 125310), Fabry disease 
(#MIM 300644), mitochondrial encephalomyopathy, lactic aci-
dosis, and stroke-like episodes (MELAS; #MIM540000), hered-
itary cerebral amyloid angiopathy (H-CAA; #MIM 605714, 
105150, and 176300), and Marfan syndrome (#MIM 174700).
Patients and Methods
Standard Protocol Approval and Patient Contents
The local ethical committees in all participating centers approved the 
study. All the patients gave informed consent for genetic testing and 
participation in the study.
Participants and Procedures
Eighteen clinical stroke centres of the Lombardia region, admitting 
>100 patients with stroke per year, and 8 high-throughput technol-
ogy genetic laboratories, performing the diagnosis of the 5 mono-
genic diseases, participated in the present study (online-only Data 
Supplement). A consecutive series of patients with ischemic or 
hemorrhagic stroke or transient ischemic attack (TIA) referred to 
the clinical participating units were recruited. Stroke physicians or 
trained researchers collected data on demographics, cerebrovascular 
risk factors, and detailed neurological and systemic clinical features 
(migraine, seizures, mood disorders, cognitive disorders, deafness, 
renal failure, high/low height, miscarriages, acroparesthesia, dys-
morphism, ligament laxity, myopathy, and skin changes) on a stan-
dardized form.4 A detailed familial history of stroke and other related 
neurological and systemic traits was obtained. The family history was 
considered positive when at least 1 disease typical disturbance was 
present in at least 1 proband’s first-degree relative.
Patients were screened for a clinically probable monogenic dis-
order using a standard procedure (Figure 1). This considered the 
presence of <3 conventional vascular risk factors (among hyperten-
sion, diabetes mellitus, hypercholesterolemia, atrial fibrillation, and 
smoking), young age at onset (≤55 years), positive familial history, 
or at least 2 associated neurological or systemic clinical features 
after the exclusion of other specific causes of stroke according to 
Trial of ORG 10172 in Acute Stroke Treatment criteria. In patients 
meeting these conditions, specific clinical and radiological diagnos-
tic algorithms for the 5 monogenic diseases were applied and those 
fulfilling the criteria for that disease (suspected) were tested for 
that specific disease. The diagnostic algorithms were implemented 
based on published clinical phenotypic information and diagnos-
tic criteria for CADASIL,4 Fabry Disease,5 MELAS,6 H-CAA,7 and 
Marfan syndrome8 (Figure 2). A full description of methods has 
been previously detailed elsewhere.3
Clinical Definitions Used
Stroke and TIA were defined according to the standard published 
clinical criteria.9,10 The presence of hypertension was defined as 
a previous diagnosis or repeated detection of a systolic blood 
pressure >140 mm Hg or a diastolic blood pressure >90 mm Hg 
in patients who were not taking antihypertensive medication.11 
Diabetes mellitus was defined according to the American Diabetes 
Association criteria.12 Hypercholesterolemia was defined as serum 
cholesterol >200 mg/dL or was considered in patients on treatment 
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with statins.13 Hyperhomocysteinemia was defined as >13 μmol/L 
for women and 17 μmol/L for men. Smoking was considered as 
present in current smokers or those who had quit smoking in the 
past 10 years. Psychiatric disorders were recorded as present in any 
of the following cases: (1) previous diagnosis of a psychiatric dis-
ease, (2) previous or current use of antipsychotic or antidepressant 
drugs, and (3) mood or behavior disorders referred by the patient 
or his or her family. Cognitive disorders were recorded as present if 
there was a previous diagnosis of cognitive impairment (mild cog-
nitive impairment or dementia) by a certified specialist or cognitive 
impairment emerged during the clinical evaluation; the presence 
of cognitive decline was referred by a next of kin or by the patient 
and confirmed by neuropsychological testing. Migraine with and 
without aura was defined according to the Headache Classification 
Committee of the International Headache Society.14 Seizures were 
defined according to the International League Against Epilepsy 
Commission Report.15
Genetic Analysis
Blood samples for DNA analysis were collected, and genomic DNA 
was extracted from peripheral blood leukocytes. Genetic and bio-
chemical analyses were performed using standard procedures as 
follows:
•	 CADASIL: direct sequencing of exons 2 to 23 of the 
NOTCH3 gene on chromosome 19 (19p13.12).
•	 Fabry disease: α-galactosidase activity dosage for 
all suspected men; sequencing of all exons of GLA 
(Xq 22,1) gene in suspected women and in men with 
decreased α-galactosidase activity or high diagnostic 
suspicion.
•	 MELAS: search for m.3243A>G mutation within the 
mitochondrial MT-TL1 gene. In cases with a high index 
of suspicion, including all those in whom a muscle biopsy 
was consistent with mitochondrial myopathy, other 
mtDNA regions were investigated by direct sequencing: 
MT-TL1, MT-TF, MT-TV, MT-TQ, MT-ND1, MT-ND5, 
and MT-ND6.
•	 H-CAA: sequencing of exon 17 of amyloid β-A4 pre-
cursor protein (APP) (21q21,3), exon 2 of cystatin C 
(CST3) 20p11,21, and exons 2, 3, and 4 of transthyretin 
(TTR) genes located at 18q12.1.
•	 Marfan syndrome: sequencing of all 65 exons of fibril-
lin-1 gene (FBN1) located on chromosome 15q21.1 and 
all 7 exons of transforming growth factor-beta receptor, 
type II (TGFβ-R2) gene on chromosome 3p24.1.
The detailed description of genetic analysis methodol-
ogy is reported in the Methods section in the online-only Data 
Supplement.
Statistical Analysis
The χ2 test was applied to assess the significant differences in fre-
quency of clinical features between patients positive and negative at 
genetic analysis. The positive predictive value was evaluated for neu-
rological or systemic clinical features and family history compared 
with the result of genetic tests. The independence of single predictive 
factors was assessed by logistic regression analysis. All analyses were 
calculated using STATA 8.0 (StataCorp LP, College Station, TX) and 
S-PLUS (Suite 44, Level 9, 88 Pitt Street Sydney New South Wales, 
Australia).
Results
During the observation period (January 2009 to December 
2012), the participating centres evaluated ≈11 000 cases of 
ischemic or hemorrhagic stroke or TIA. Of these, 253 patients 
met the criteria for stroke of probable genetic origin and were 
included in the study by the recruiting centres, but on central 
review, 44 were excluded because they did not fulfil the inclu-
sion criteria. Therefore, 209 patients with stroke/TIA were 
included (Figure 1).
Full demographic details of the patients are shown in 
Table 1. The mean age was 57.4±14.7 years; 45% were 
women. The index event was stroke in 163 (78%) and TIA 
in 46 (22%). Of the 163 patients with stroke, stroke was isch-
emic in 112 (69%) and hemorrhagic in 51 (31%; information 
missing in 1 case). In 45% of cases, stroke was the first event, 
whereas 51% of patients had experienced ≥2 events in the past 
history (information was not available in 9 cases).
After following the disease-specific clinical screening 
algorithms, genetic test was performed for CADASIL in 103 
cases (41%), Fabry disease in 33 (13%), H-CAA in 70 (28%), 
MELAS in 16 (6%), and Marfan syndrome in 5 (2%). Because 
18 patients met the criteria for >1 genetic disease, a total of 
227 tests were performed in the 209 patients.
A monogenic disease was genetically confirmed in 14 
cases: 9 were diagnosed as CADASIL, 1 as Fabry disease, 
1 as H-CAA, 2 as MELAS, and 1 as Marfan syndrome. One 
patient negative for genetic screening for Marfan syndrome 
was subsequently found to have an Ehlers–Danlos type IV 
disease (COL3A1 gene) mutation. Table 2 summarizes the 
detailed results of genetic analysis.16–23
Clinical and demographic characteristics were compared 
between individuals positive and negative on genetic testing 
(Table 3). The only significant difference was a family his-
tory of stroke (92% versus 47%; P=0.002). It is of note that 
Figure 1. Diagnostic flowchart. CADASIL indicates cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; CVRF, cardiovascular risk factors; and TIA, 
transient ischemic attack.
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positive genetic tests occurred in many patients with conven-
tional cardiovascular risk factors.
We calculated the positive predictive value of the dis-
ease-associated neurological or systemic clinical features 
and of positive familial history (Table 4). The positive pre-
dictive value was >10% for psychiatric disorders, cognitive 
disorders, high/low height, and familial history of stroke, 
migraine, psychiatric disorders, and dementia. However, 
only family history of stroke was significantly associ-
ated with a genetic diagnosis. Multiple logistic regression 
analysis confirmed the independent statistically signifi-
cant association between a positive genetic test and a fam-
ily history of stroke (odds ratio, 4.8; confidence interval, 
1.45–15.70).
Discussion
This study found that the adoption of a phenotype-based algo-
rithm for the identification of patients tested for monogenic 
stroke conditions resulted in a diagnostic of ≈7%, in contrast 
to previously reported yields of 1% to 5%.1,2
Genetic testing is expensive, and counseling can be time 
consuming. Therefore, guidance on the type of patients in 
whom there is a yield sufficient to merit testing is impor-
tant. There have been a few previous attempts to develop 
pregenetic screening strategies for monogenic stroke dis-
orders, but methods were heterogeneous. This study pro-
vides some of the most robust data to guide current clinical 
practice.6,24–26
Our strategy identified 7% of patients affected by mono-
genic diseases. Our criteria seem to be particularly efficient 
for CADASIL pregenetic screening because we detected 
disease-related mutations in 9% of our suspected cases. 
The strength of this study is that the screening strategy was 
implemented in a prospectively collected and well-pheno-
typed series of patients with stroke using novel diagnostic 
criteria. Many previous studies have been retrospective on 
populations in whom there may be significant selection 
bias.24–26
Although our study shows that using our algorithm we 
achieved a relatively high yield of positive cases, it does not 
evaluate the effectiveness of the algorithm in diagnosing all 
Figure 2. Clinical algorithms for diagnosis of monogenic disorders. MRI indicates magnetic resonance imaging; and TIA, transient 
ischemic attack.
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cases of monogenic strokes in a stroke population. This would 
have required genetic testing in patients in whom the algo-
rithm did not suggest a high probability of monogenic stroke. 
However, such study design, which has never been applied 
in previous studies, would require huge funding support. 
Moreover, the results of recent studies screening systemati-
cally patients with stroke for monogenic diseases did not find 
higher disease frequencies,27 supporting the idea that the use 
of more narrow selection criteria is more favorable for identi-
fying an higher number of positive patients.
Potential further limitations of the study are that we used 
a hospital-based sampling frame and the relatively small 
number of cases in whom genetic testing was performed. 
Another limit is that we only tested patients for 5 mono-
genic causes of stroke, whereas more recently described 
causes, such as COL4A1 and CARASIL, have not been 
included in our screening.28 Furthermore, there was a rela-
tively low National Institutes of Health Stroke Scale score 
although this is similar to that in previous studies29,30 and 
may partly reflect the lower National Institutes of Health 
Stroke Scale associated with lacunar strokes in diseases, 
such as CADASIL.
Differently from previous series, no patient presenting 
with TIA as index event resulted carrier of a monogenic 
disease. This finding may be explained by chance alone 
although it cannot be excluded that patients included in the 
study as stroke might have presented previously with a TIA.
Our results also highlight many important elements that 
should be considered in the investigation of monogenic causes 
of stroke. First, common cerebrovascular risk factors, in par-
ticular hypertension, diabetes mellitus, hypercholesterolemia, 
and smoke, should not be considered as exclusion criteria for 
genetic screening. Furthermore, the concomitant presence of 
cerebrovascular risk factors may be important to take into 
account because recent evidence suggests that they may inter-
act to increase phenotype severity even in monogenic stroke 
patients.31,32 Second, familial history, particularly of stroke, 
should probably be considered as mandatory for genetic 
screening unless familial history is unavailable or first-degree 
relatives died of other causes at an age before they might have 
Table 1. Demographic and Clinical Features and Risk Factors 
of Patients With Suspected Monogenic Disease
Clinical Features Overall Patients, n=209
Age, y, mean±SD 57.4±14.7
Female sex, n (%) 95 (45)
Lombardia region birth, n (%) 126 (60)
Stroke* 163 (78)
NIHSS mean±SD 4±4.9
First event† 93 (45)
≥2 events‡ 54 (51%)
Risk factors
  Hypertension 106 (51%)
  Diabetes mellitus 22 (11%)
  Current smoker 75 (36%)
  Atrial fibrillation 8 (4%)
  Hypercholesterolemia 84 (40%)
  Ischemic cardiomyopathy 13 (6%)
  Peripheral arteriopathy 6 (3%)
  Hormone therapy 11 (5%)
  Alcohol intake, >20 U/wk 4 (2%)
  BMI, >25 kg/m2 63 (30%)
  Physical inactivity 108 (52%)
BMI indicates body mass index; and NIHSS, National Institutes of Health 
Stroke Scale.
*Information missing in 1 case.
†Information missing in 9 cases.
‡Information missing in 84 cases.
Table 2. Results of Genetic Tests
Disease
n (%) of Tests,  
n=227
n (%) of Positive  
Tests, n=14 Gene Type of Event Mutation (cDNA) Exon
CADASIL 103 9 (9) NOTCH3 Left carotid TIA (aphasia) c.268C>T (Shahien et al16) 3
Lacunar stroke c.328C>T (Joutel et al17) 3
Lacunar stroke c.349T>C (Wang et al18) 4
Lacunar stroke c.752G>A (Mykkänen et al19) 5
Lacunar stroke c.1732C>T (Joutel17 et al) 11
Vertebrobasilar TIA c.1819C>T (Escary et al20) 11
Lacunar stroke c.2953C>T (Joutel17 et al) 18
Vertebrobasilar lacunar stroke c.2953C>T (Joutel et al17) 18
Lacunar stroke c.3691C>T (Joutel et al17) 22
Fabry disease 33 1(3) GLA Ischemic cortical–subcortical stroke c. 187T>G (Shabbeer et al21) 6
H-CAA 70 1 (1) APP Hemorrhagic stroke c.2077G>A (Bugiani et al22) 17
MELAS 16 2 (12) MT-TL1 Ischemic cortical–subcortical stroke m.3243A>G (Goto et al23) //
Marfan syndrome 5 1 (20) FBN1 Hemorrhagic stroke c.1185T>G* 10
CADASIL indicates cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; H-CAA, hereditary cerebral amyloid angiopathy; 
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; and TIA, transient ischemic attack.
*New mutation.
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expressed the disease. In contrast, other specific clinical and 
familial factors (ie, familial history of migraine, epilepsy, and 
psychiatric disorders) were not predictive of an underlying 
genetic diagnosis.
We found a low prevalence of H-CAA, Fabry disease, or 
Marfan syndrome in our series. This may be because of 2 rea-
sons. First, these diseases are really rare in stroke populations. 
Consistent with this, although Fabry disease was suggested 
as an important cause of younger onset stroke in 1 study,33–35 
further studies have failed to replicate this finding. Second, 
the diagnostic algorithms may not adequately address these 
diseases.36
Conclusions
To make the diagnosis of monogenic diseases is important 
not only for the individual patient but also for family mem-
bers to allow the possibility of predictive testing. However, 
the diagnosis is often challenging because of the overlapping 
phenotypes between each disorder and the heterogeneity of 
phenotypes within families. The current study, in which 
genetic testing was performed in cases identified using a 
clinical algorithm, found that 7% of patients were affected 
by monogenic diseases. Family history is a key feature for 
a clinical suspicion of monogenic disease, whereas stroke in 
the absence of cardiovascular risk was not a useful marker of 
a monogenic diagnosis.
Table 3. Clinical Features of Patients Positive and Negative 
at Genetic Analysis
Clinical Features
Positive  
Patients, n=14
Negative 
Patients, n=195 P Value
Age, y, mean±SD 50.6±14.8 57.8±14.7 0.08
Female sex 7 (50%) 88 (45%) ns
Lombardia region birth 11 (78%) 115(59%) ns
Stroke* 10 (71%) 153 (78%) ns
  Ischemic stroke* 8 (57%) 104 (53%) ns
  Hemorrhagic stroke 2 (14%) 49 (25%) ns
TIA 4 (29%) 38 (19%) ns
NIHSS, mean±SD 4.4±5.2 3.9±4.9 ns
First event† 7 (50%) 89 (45%) ns
≥2 events‡ 5 (36%) 42 (21%) ns
Hypertension 6 (43%) 100 (51%) ns
Diabetes mellitus 3 (21%) 19 (10%) ns
Current smoker 6 (42%) 69 (35%) ns
Atrial fibrillation 0 8(4%) ns
Ischemic cardiomyopathy 2 (14%) 11 (6%) ns
Hypercolesterolemia 8 (57%) 76 (39%) ns
Peripheral arteriopathy 1 (7%) 5 (2%) ns
Hormone therapy 0 11 (6%) ns
Alcohol intake 0 4(2%) ns
BMI, >25 kg/m2 4(2%) 54(28%) ns
Physical inactivity 6 (43%) 102 (52%) ns
Migraine 7 (50%) 83 (43%) ns
Seizures 1 (7%) 40 (20%) ns
Psychiatric disorders 4 (29%) 47 (24%) ns
  Mood disorders 4 (29%) 34 (17%) ns
Cognitive disorders 5 (36%) 51 (26%) ns
Deafness 0 14 (7%) ns
Renal failure 0 11 (6%) ns
High/low height 2 (14%) 19 (10%) ns
Miscarriages 0 9 (5%) ns
Acroparesthesia 1 (7%) 18 (9%) ns
Dysmorphism 0 3 (1%) ns
Ligament laxity 0 5 (21%) ns
Myopathy 0 4 (2%) ns
Skin changes 0 0 ns
Family history
  Stroke 12/13 (92%) 72/154 (47%) 0.002§
  Migraine 4/12 (33%) 42/149 (28%) ns
  Epilepsy 0/12 9/145 (6%) ns
  Psychiatric disorders 2/12 (16%) 20/150(13%) ns
  Dementia 3/13 (23%) 37/148(25%) ns
BMI indicates body mass index; NIHSS, National Institutes of Health Stroke 
Scale; ns, nonsignificant; and TIA, transient ischemic attack.
*Information missing in 1 case.
†Information missing in 9 cases.
‡Information missing in 84 cases.
§Significant association.
Table 4. PPV of Clinical Features and Family History
Overall Patients, 
n=209
Positive Cases  
at Genetic 
Analysis, n=14 PPV
Symptoms
  Migraine 90 (43%) 7 0.5
  Seizures 41 (19%) 1 0.07
  Psychiatric disorders 51 (24%) 4 0.28
  Cognitive disorders 56 (27%) 5 0.35
  Deafness 14 (7%) 0 0
  Renal failure 11 (5%) 0 0
  Low/high height 21(10%) 2 0.14
  Miscarriages 9 (4%) 0 0
  Acroparesthesia 19 (9%) 1 0.07
  Dysmorphism 3 (1%) 0 0
  Ligament laxity 5 (2%) 0 0
  Miopathy 4 (2%) 0 0
  Skin changes 0 0 0
Family history
  Stroke 84/167 (50%) 12/13 0.86
  Migraine 46/161 (29%) 4/12 0.28
  Epilepsy 9/157 (6%) 0/12 0
  Psychiatric disorders 22/161 (14%) 2/12 0.14
  Dementia 40/161 (25%) 3/13 0.21
PPV indicates positive predictive value.
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SUPPLEMENTAL MATERIAL 
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Supplemental Table I. Clinical algorithms for diagnosis of monogenic disorders  
 
CADASIL 
 
1)  Subcortical lacunar T2 sequence lesions at MRI.                                                                       
2)  At least one of the following sign/symptoms 
 History of recurrent stroke /TIA  
 Migraine with aura 
 Dementia 
 Major mood disorders 
 Familial history of stroke/mood disorders and/or migraine and/or dementia   
 
 
FABRY DISEASE 
 
1) Not atherosclerotic stroke (mostly vertebrobasilar and lacunar)  
2) At least one of the following sign/symptoms: 
 Acroparesthesia/ neuropatic pain (recurrent hands and feet pain)  
 White matter hyperintensities detected on MRI 
 Angiokeratoma  
 Corneal lesions: “Cornea verticillata”  
 Seizures 
 Renal involvement (proteinuria, chronic renal failure) 
 Cardiac involvement 
 
MELAS 
 
1) Stroke-like episodes (mostly cortical and not related to a vascular territory) in patients younger than 45 
years  
2) At least one of the following sign/symptoms:  
 Miopathy with lactic acidosis 
 Seizures 
 Migraine 
 MRI typical lesions (bitemporal and basal ganglia calcification)  
 Cardiomiopathy 
 Progressive dementia 
 Mental retardation 
 Short stature  
 Diabetes 
 
FAMILIAL OR SPORADIC HEMIPLEGIC MIGRAINE (FHM/SHM) 
1) At least two aura migraine attacks associated with motor weakness (hemiparesis, paresis, plegia) 
lasting >5 min e <24 h 
2) At least one of the following signs/symptoms: 
 Fully reversible visual symptoms including positive features (i.e, flickering lights, spots or 
lines) and/or negative features (i.e, loss of vision) 
 Fully reversible sensory symptoms including positive features (ie, pins and needles) and/or 
negative features (i.e numbness) 
 Fully reversible dysphasic speech disturbance 
 Supplementary clinical features:  
 Migraine following aura. 
 Childhood onset migraine  (<30 years)  
 At least one first- or second-degree relative has had attacks fulfilling these criteria  
 Progressive ataxia  e/o nystagmus 
 Attacks triggered by fever, trauma, pleiocitosys 
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CEREBRAL HERITABLE AMYLOID ANGIOPATHY (H-CAA) 
 
1) At least one of the following signs 
 Recurrent atypical haemorrhages (mostly cortical and subcortical) 
 Ischemic/haemorrhagic lesions not attributable to a different disorder 
 Cerebral MRI consistent with the suspicion of amyloid angiopathy 
 
2) At least one of the following signs/symptoms: 
 Lack of hypertension or well treated hypertension), lack of coagulation abnormalities  
 Absence of aneurysms or arterovenous malformations 
 Positive familial history for haemorrhagic and ischemic stroke 
 Cognitive impairment 
 Occipital calcifications 
 
 
MARFAN SYNDROME 
 
1) Ischemic or haemorrhagic stroke due to arterial dissection, intracranial aneurysms rupture or 
cardioembolic source  
2) At least two of the following criteria:  
 At least two skeletal abnormalities (high stature, pectus excavatum or carinatum, high-arched 
palate, arachnodactyly, laxity of ligaments with scoliosis or joint hyperextensibility  
 At least two ocular manifestations (strabismus, amblyopia, ectopia lentis, and cataract)  
 At least one cardiovascular manifestation (dissection or dilatation of ascending aorta, mitral 
valve prolapse and cardiac arrhythmias) 
 At least one cutaneous manifestation (cutaneous lines, recurrent hernias)  
 At least one pulmonary manifestation (spontaneous pneumothorax, apical bubbles) 
 Positive familial history for arterial dissections, skeletal abnormalities, typical cardiovascular 
and ocular manifestations)  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Supplemental Methods: Genetic analysis methodology  
 
CADASIL (#MIM 125310) 
DNA was extracted from whole blood samples using standard procedures. Genetic test were performed by direct 
automated sequencing of the coding and flanking regions of the disease genes. CADASIL DNA amplification was 
performed by using primers, kindly provided by Prof. Dichgans (Ludwig Maximilians University, Munich, 
Germany), designed to amplify the 2-23 exons of the NOTCH3 gene, including the intron-exon boundaries. The PCR 
reactions were performed using AmpliTaq Gold® DNA polymerase (Applied Biosystems). Direct sequence was 
performed on an automated sequencing system (Applied Biosystems 3730 DNA Analyzer) using the BigDye™ 
Terminator Cycle Sequencing Kit Version 1.1 (Applied Biosystems). Sequencing of exons 3, 4, 6 and 8 was done 
first; screening of the 18 remaining exons encoding the EGF repeats was pursued until a mutation creating or 
deleting a cysteine residue was identified. The nucleotide position of mutation present in the coding regions refers to 
the mRNA sequence (NM_000435). 
 
Fabry disease (#MIM 300644)  
The 7 exons of the GLA gene were amplified from peripheral blood-derived genomic deoxyribonucleic acid by 
means of polymerase chain reaction.The polymerase chain reaction fragments were analyzed by means of denaturing 
high-performance liquid chromatography using the Wave deoxyribonucleic acid fragment analysis system 
(Transgenomic, San Jose, California). Heteroduplex fragments were purified (QIAquick Kit, Qiagen, Santa Clarita, 
California) and then sequenced using a BigDye-terminator cycle sequencing system (ABI PRISM, Applied 
Biosystems, Foster City, California). Reference sequence used in the study is NM_000169. 
 
MELAS (#MIM540000) 
 The presence of the m.3243A>G mutation was investigated by PCR amplification (primers: FOR3150, RC3380) 
followed by restriction fragment length polymorphisms (RFLP) analysis using the HaeIII restriction endonuclease. 
The quantification of mtDNA heteroplasmy was calculated by densitometry after gel electrophoresis or using a 
Taqman-based quantitative PCR protocol (FOR: 5’-CCACACCCACCCAAGAACAG-3’; RC: 5’-
AGGAATTGAACCTCTGACTGTAAAGTT-3’; probe 6-FAM-CCGGGCCCTGCCAT-MGB). Other mtDNA 
regions were analyzed by direct sequencing using the MitoSeq Resequencing system (Applied Byosisytems). 
 
MARFAN SYNDROME(#MIM 174700):  
FBN1 gene (MIM 134797): Sanger sequencing of the exons and exon-intron boundaries of FBN1 was performed on 
genomic DNA. Genomic DNA was isolated from peripheral blood leukocytes by the QIAmp DNA blood kit (Qiagen 
Inc., Valencia, CA, USA).  The analysis was performed  by direct automated sequencing  using the BigDye 
Terminator Cycle sequencing kit V 3.1 (Applied Biosystems) on an ABI 3100 Genetic Analyzer, following the 
manufacturer's directions. 
TGFBR2 gene (MIM 190182):The seven exons and flanking regions of the TGFBR2 were amplified using 
previously reported intron-specific primers, with the exception of three amplicons (exons 1, 2 and 5) for which the 
two primers were newly designed using the Amplify 1.0 software:(1F:5'TCCGGGAAGGCGCCGTCCGCT3',1R: 
5'CGACTGTCAAGCGCAGCGGAGAG3';2F:5'GCTGCCTGGCAGTTGGATAAT3',2R:5'ACACTGACTGTGTG
TACTATG3';5F:5'AATGATGGGCCTCACTGTCT3', 5R: 5'ACACAATGATGCTGGTCCAC3'). The analysis was 
performed by direct automated sequencing. Direct sequencing analysis was performed using the BigDye Terminator 
Cycle sequencing kit V 3.1 (Applied Biosystems) on an ABI 3100 Genetic Analyzer, following the manufacturer's 
directions 
 
HCAA(#MIM 605714, 105150, 176300) 
The following coding regions were analyzed by direct Sanger sequencing: 1) exon 17 of APP gene; 2) exons 2, 3, 
and 4 of TTR gene; exon 2 of CST3 gene. Primers designed in flanking intronic regions were used for PCR 
amplification. After purification of PCR products, sequencing reactions were performed by dye-terminator cycle 
sequencing according to manufacturer’s instructions and loaded on an ABI Prism 3500 DNA analyzer. 
 
FHM/SHM (#MIM 601011, 602481, 141500):  The following genes have been analysed by direct Sanger 
sequencing of coding regions and flanking intron sequences as described previously [Condliffe SB, Fratangeli A, 
Munasinghe NR, Saba E, Passafaro M, Montrasio C, Ferrari M, Rosa P, Carrera P, The E1015K variant in the 
synprint region of the Cav2.1 channel alters channel function and is associated with different migraine phenotypes, 
The J of Biological Chemistry, 2013, 288:33837-33883]: CACNA1A (FHM1-OMIM 141500), ATP1A2 (FHM2-
OMIM 602481), SCN1A (FHM3-OMIM 609634). (http://genome.ucsc.edu/cgi-bin/hgGateway). 
The PCR products and sequencing reactions were purified on Multiscreen 96 PCR plates (Millipore) and G50 
Multiscreen TM-HV plates (Millipore) respectively, using the automated liquid handling system Biomeck FX 
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(Beckmann Coulter). Dye-terminator cycle sequencing reactions were set up following the manufacturer’s 
instructions and loaded on a ABI Prism 3730 DNA Analyzer (Applied Biosystems). Called sequences were 
assembled and compared with the reference sequences in genomic databases (CACNA1A, LRG_7; ATP1A2, 
LRG_6;  SCN1A, LRG_8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
